Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasmid), for severe peripheral vascular disease (PVD).
The product obtained Japanese conditional approval in 2019 and had been filed for full approval in 2023